about
Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies.Procoagulant mechanisms in tumour cells.Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemiaPathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.Mechanisms of thrombosis in cancer.The coagulopathy of cancer.The mechanisms of cancer-associated thrombosis.LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.Platelet haemostatic properties in β-thalassaemia: the effect of blood transfusion.ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.Clinical characteristics and genetic analysis in women with premature ovarian insufficiency.Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism.Mechanisms and risk factors of thrombosis in cancer.Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia veraV617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules
P50
Q33399611-A4121962-A7BD-4541-B149-EE23AFF80E10Q37414578-183E108A-35A6-4075-A9E2-E56711920637Q37625070-027EEBD8-482A-45CE-882E-C735C5204868Q37973346-E6A02664-0CA8-4557-9A37-7341367BA9EEQ38085785-F243936C-B4A0-435E-9096-40B98BC41266Q38233153-0282CF0C-43FB-4BD2-9C4C-BB69484E7196Q38436414-99EA3CF6-DDDB-4B77-A908-AB6D22EE3E62Q39603869-2390E10D-930F-4CDB-8A67-87FB756D2664Q41547084-59CFE4B2-8FB0-4DCD-9A2D-4DB06CDBC255Q42439502-4C0A9E36-AB32-4A62-86E3-532D357FF442Q46082030-BE3D8FAE-055E-4100-9EB2-AFAD35908591Q47201370-6AD77737-AFED-4A62-830C-7C9A1C41A3D7Q47792527-A73F3AF0-DE56-4FAE-A34B-9D101D6E2EC7Q50135977-70E516CD-E954-44BC-A1D4-BE9573A365F9Q50644888-567BD869-08C5-423B-81F7-3B1614FA491FQ54574840-79E8D935-01F6-4400-BF8A-D76B782201AEQ63367974-300343D7-9ABF-4CBC-93E0-9CE2AAA4A93DQ80497559-A08CAF55-BF48-4BBB-8500-D19DB9C13D02
P50
description
researcher ORCID 0000-0003-0018-7090
@en
name
Laura Russo
@ast
Laura Russo
@en
Laura Russo
@es
Laura Russo
@nl
type
label
Laura Russo
@ast
Laura Russo
@en
Laura Russo
@es
Laura Russo
@nl
prefLabel
Laura Russo
@ast
Laura Russo
@en
Laura Russo
@es
Laura Russo
@nl
P106
P1153
35798991400
P21
P31
P496
0000-0003-0018-7090